Responses
EULAR 2014: Scientific Abstracts
Poster Presentations. Rheumatoid arthritis - prognosis, predictors and outcome
THU0242 Vx-509 (DECERNOTINIB) Treatment Reduces Levels of Markers for Immune Activation, Bone Degradation and Inflammation but not Interferon Signaling in Patients with Rheumatoid Arthritis
Compose a Response to This Article
Other responses
No responses have been published for this article.